- Home
- PHAT
as 07-26-2024 4:00pm EST
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | FLORHAM PARK |
| Market Cap: | 610.5M | IPO Year: | 2019 |
| Target Price: | $22.00 | AVG Volume (30 days): | 859.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.47 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.07 - $17.02 | Next Earning Date: | 08-08-2024 |
| Revenue: | $2,594,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 6153.81% | Revenue Growth (next year): | 291.39% |
Stock Insider Trading Activity of Phathom Pharmaceuticals Inc. (PHAT)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Henderson Molly | PHAT | CFO and CBO | Apr 8 '24 | Sell | $11.10 | 3,435 | $38,128.50 | 95,263 | SEC Form 4 |
| Curran Terrie | PHAT | President and Chief Executive | Mar 22 '24 | Sell | $9.11 | 16,851 | $153,512.61 | 410,784 | SEC Form 4 |
| TAKEDA PHARMACEUTICAL CO LTD | PHAT | 10% Owner | Jan 24 '24 | Sell | $8.10 | 3,703,703 | $29,999,994.30 | 3,755,583 | SEC Form 4 |
| Henderson Molly | PHAT | CFO and CBO | Jan 18 '24 | Sell | $7.75 | 6,307 | $48,900.06 | 98,698 | SEC Form 4 |
| Henderson Molly | PHAT | CFO and CBO | Nov 20 '23 | Sell | $7.24 | 2,127 | $15,402.67 | 103,061 | SEC Form 4 |
| Parikh Asit | PHAT | Director | Nov 6 '23 | Buy | $8.04 | 1,000 | $8,040.00 | 48,500 | SEC Form 4 |
| Parikh Asit | PHAT | Director | Nov 6 '23 | Buy | $7.76 | 4,000 | $31,040.00 | 52,500 | SEC Form 4 |
| Parikh Asit | PHAT | Director | Nov 6 '23 | Buy | $7.80 | 2,500 | $19,500.00 | 55,000 | SEC Form 4 |
Latest Phathom Pharmaceuticals Inc. News
PHAT Breaking Stock News: Dive into PHAT Ticker-Specific Updates for Smart Investing
MT Newswires
8 days ago
Phathom Pharmaceuticals Gets New FDA Approval for Voquezna Tablets
Argus Research
9 days ago
Daily – Vickers Top Buyers & Sellers for 07/18/2024
GlobeNewswire
9 days ago
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults
GlobeNewswire
2 months ago
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
GlobeNewswire
2 months ago
Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2024 Annual Meeting
Insider Monkey
2 months ago
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q1 2024 Earnings Call Transcript
Zacks
3 months ago
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Lags Revenue Estimates
GlobeNewswire
3 months ago
Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
Compare PHAT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PHAT Phathom Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.